Pfizer Inc. has published the transcript of its Fourth Quarter 2025 earnings conference call, which took place on February 3, 2026. The event provided an overview of the company's financial results for Q4 and the full year 2025. Key participants included Pfizer’s Chairman and CEO Dr. Albert Bourla, Chief Scientific Officer Dr. Chris Boshoff, Chief Financial Officer David Denton, Chief Investor Relations Officer Francesca DeMartino, and other senior executives. During the call, management highlighted Pfizer's performance and reaffirmed confidence in its commercial capabilities and portfolio. “We have a lot of confidence in our ability to win commercially in this market with these assets,” said the Chief Executive Officer, emphasizing the strength of Pfizer’s field forces and digital platforms, including the “Pfizer For All” initiative that has reached over 25 million patients. The leadership team also addressed forward-looking statements and discussed risks and uncertainties, reminding listeners to review relevant disclaimers and SEC filings. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on February 10, 2026, and is solely responsible for the information contained therein.